Data Insights

CABA-201 by Cabaletta Bio for Immune Mediated Necrotizing Myopathy (IMNM): Likelihood of Approval

CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Immune Mediated Necrotizing Myopathy (IMNM). According...

Likelihood of Approval and Phase Transition Success Rate Model - CABA-201 in Immune Mediated Necrotizing Myopathy (IMNM)

Data Insights

CABA-201 by Cabaletta Bio for Dermatomyositis: Likelihood of Approval

CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - CABA-201 in Dermatomyositis

Data Insights

CABA-201 by Cabaletta Bio for Idiopathic Inflammatory Myopathy (IIM): Likelihood of Approval

CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM). According to...

Likelihood of Approval and Phase Transition Success Rate Model - CABA-201 in Idiopathic Inflammatory Myopathy (IIM)

Data Insights

CABA-201 by Cabaletta Bio for Lupus Nephritis: Likelihood of Approval

CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - CABA-201 in Lupus Nephritis

Data Insights

CABA-201 by Cabaletta Bio for Systemic Lupus Erythematosus: Likelihood of Approval

CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - CABA-201 in Systemic Lupus Erythematosus

Data Insights

CABA-201 by Cabaletta Bio for Systemic Sclerosis (Scleroderma): Likelihood of Approval

CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData,...

Data Insights

CABA-201 by Cabaletta Bio for Myasthenia Gravis: Likelihood of Approval

CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Myasthenia Gravis. According to GlobalData, Phase...

Data Insights

Risk adjusted net present value: What is the current valuation of Cabaletta Bio's CABA-201?

CABA-201 is a gene-modified cell therapy commercialized by Cabaletta Bio, with a leading Phase II program in Systemic Sclerosis (Scleroderma)....

Net Present Value Model: Cabaletta Bio Inc's CABA-201

Data Insights

Risk adjusted net present value: What is the current valuation of Cabaletta Bio's CABA-201?

CABA-201 is a gene-modified cell therapy commercialized by Cabaletta Bio, with a leading Phase II program in Dermatomyositis. According to...

Net Present Value Model: Cabaletta Bio Inc's CABA-201